{"id":4736,"date":"2021-09-30T13:34:54","date_gmt":"2021-09-30T13:34:54","guid":{"rendered":"https:\/\/stuarttherapeutics.com\/?page_id=4736"},"modified":"2021-09-30T17:34:20","modified_gmt":"2021-09-30T17:34:20","slug":"st-pipeline","status":"publish","type":"page","link":"https:\/\/stuarttherapeutics.com\/st-pipeline\/","title":{"rendered":"ST Pipeline"},"content":{"rendered":"
PolyCol\u2019s<\/strong><\/em> ability to rapidly repair the damaged collagen present in dry eye disease, coupled with the concurrent recovery of the corneal epithelium and reduction of inflammation, make this the company\u2019s initial focus through the drug candidate ST-100. Future development opportunities for this ocular surface drop formulation include Allergic Conjunctivitis, Corneal Trauma, and Corneal Ulcers. The development of ST-100 is supported by compelling animal testing results, with complete healing of damaged corneal tissues in 24 hours or less. Other variants of the PolyCol<\/strong><\/em> platform have demonstrated promise in two major diseases with significant unmet need: Glaucoma and Dry Age-Related Macular Degeneration (Dry AMD). Stuart has completed a series of research programs that demonstrate the benefits of repair and restoration of triple helix collagen in the affected tissues commonly associated with both of these disease indications. These results suggest a completely novel approach to treating these chronic indications.<\/p>\n<\/div>